trivalent ganglioside vaccine / MabVax - LARVOL DELTA

A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery (Eur J Cancer) - P2 | N=136 | NCT01141491 | Sponsor: MabVax Therapeutics, Inc. | "Histologies included leiomyosarcoma (33%), spindle cell sarcoma (14%), undifferentiated pleomorphic sarcoma (13%), osteosarcoma (10%), synovial sarcoma (9%), liposarcoma (9%) and others (12%)....The 1-year relapse-free survival rate (34.5% and 34.8% in the vaccine and OPT-821 monotherapy arm, respectively) did not differ between arms (P = 0.725). One-year overall survival rates were 93.1% and 91.5% in the vaccine and OPT-821 monotherapy arm, respectively (P = 0.578). Serologic responses at week 9 were more frequent on the vaccine arm (96.5% of patients) than in the adjuvant arm (32.8%), and the difference between groups was durable."

P2 data • Leiomyosarcoma • Oncology • Osteosarcoma • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Spindle Cell Sarcoma • Synovial Sarcoma • Undifferentiated Pleomorphic Sarcoma

A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery. (PubMed, Eur J Cancer) - P2 | "A sustained serologic response to vaccination was induced with the vaccine, but no difference in recurrence-free or overall survival was observed between treatment arms."

Journal • P2 data • Fatigue • Immunology • Leiomyosarcoma • Liposarcoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • Spindle Cell Sarcoma • Synovial Sarcoma • Undifferentiated Pleomorphic Sarcoma